Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnoses of possible or probable Alzheimer's disease (NINCDS-ADRDA)~2. Presence of a caregiver (friend or relative) who can assume responsibility for medication compliance, can accompany the patient to all visits, and rate patient's condition~3. Written informed consent from both the patient (or surrogate) and caregiver~4. An MMSE score between 12 and 26 inclusive~5. Administration of a maintenance dosage of donepezil (5-10mg/d), rivastigmine (6-12mg/d) or rivastigmine (Exelon) patch (4.6 mg or 9.5 mg), galantamine or galantamine ER (16-24mg/d) for a minimum of 4 weeks prior to randomization~6. Agreement not to take vitamin E supplements and/or memantine outside of the study (daily multivitamin is permitted containing up to 100 IU alpha-tocopherol)~Exclusion Criteria:~1. A non-Alzheimer primary dementia (e.g., vascular dementia, Lewy body dementia, fronto-temporal dementia, vitamin B-12 deficiency, hypothyroidism)~2. Current major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder as defined by DSM-IV~3. Presence of any uncontrolled systemic illness that would interfere with participation in the study or a life expectancy of less than one year~4. Pregnant or intention to become pregnant~5. Enrollment in another interventional clinical trial~6. Current prescription with more than one AChE inhibitor~7. Current prescription for warfarin~8. Use of vitamin E supplements in the past 2 weeks~9. Use of memantine in the past 4 weeks or known intolerance~10. Estimated creatinine clearance less than 5ml/min (Cockcroft-Gault formula)~11. Use of amantadine in the past 2 weeks

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
- Arm 2 (Type: EXPERIMENTAL): 20 mg per day of memantine plus placebo for dl-alpha-tocopherol
- Arm 3 (Type: EXPERIMENTAL): Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
- Arm 4 (Type: PLACEBO_COMPARATOR): Matching placebos for dl-alpha-tocopherol and memantine

Based on this trial design, predict the completion outcome and termination type (if applicable).